ENTA

Enanta Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↑ 7/10
  • Value↓ 0/10
Enanta Pharmaceuticals sales and earnings growth
ENTA Growth
Good
  • Revenue Y/Y↓ 0.58%
  • EPS Y/Y↑ 35.15%
  • FCF Y/Y↑ 80.86%
Enanta Pharmaceuticals gross and profit margin trends
ENTA Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -106.80%
  • ROIC 5Y↓ -33.18%
Enanta Pharmaceuticals net debt vs free cash flow
ENTA Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↓ 1.1
  • Interest coverage↓ -7.3

Enanta Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗